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Abstract
Scientific evidence for the effects of Terminalia arjuna on diabetes mellitus 
is lacking. This study investigated the anti-diabetic efficacy and mode of action 
of the bark extract of Terminalia arjuna. Insulin-release from BRIN-BD11 cells 
was assessed in the absence or presence of T. arjuna extracts and modulators 
of insulin-secretion. Insulin concentration and intracellular calcium ([Ca2+]i) were 
measured by radioimmunoassay and FLEXstationTM respectively. Adipocyte 
glucose-uptake with 3T3-L1 fibroblasts, starch digestion with α-amylase and 
protein glycation were assessed in vitro. Terminalia arjuna extract stimulated 
insulin-release alone (p<0.001), in combination with known modulators but not 
without extracellular Ca2+. It increased intracellular calcium but had no effects on 
depolarised cells. Glucose-uptake was enhanced in the presence of T. arjuna 
(P< 0.001). At higher concentrations, the extract decreased starch digestion 
and inhibited protein glycation (p<0.001). Terminalia arjuna extract possesses 
antidiabetic potential and may provide new opportunities for the treatment of 
diabetes.
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pain, and in the treatment of coronary artery disease, heart failure and 
possibly hypercholesterolemia [14,15]. Ragavan and Krishnakumari 
[12] provided evidence for the beneficial effects of T. arjuna bark 
extracts in relation to the treatment of diabetes, reporting a reduction 
in serum glucose as well as protection against the destruction of 
pancreatic beta cells and kidney damage in rats with alloxan-induced 
diabetes. However, data on the effects of extracts of T. arjuna on 
insulin secretion and the mechanism behind its anti-diabetic effects 
are lacking.   The aim of the present study was to investigate actions 
of Terminilia arjuna bark extract on insulin secretion and glucose 
uptake at the cellular level.  Furthermore, possible effects on protein 
glycation and starch digestion were examined in vitro. 
Materials and Methods
Plant material
Dried bark of Terminalia arjuna was obtained from a commercial 
supplier, Cure Herbs Pvt, Delhi, India. A voucher specimen of the 
plant is available in the company. Bark was homogenised to a fine 
powder and stored in opaque screw-top jars at room temperature (20 
ºC ± 2 o C) until use.  For in vitro work, a decoction was prepared 
by bringing 25 g/l (dry weight) of material to the boil in water and 
allowed to infuse over 15 minutes.  The suspension was filtered 
(Whatman No.1 filter paper) and the volume adjusted so the final 
concentration was 25 g/l. Aliquots (1 ml) of the filtered plant solution 
was brought to dryness under vacuum (Savant Speed vac, Savant 
Instrumentation Incorp., NY, USA).  Dried fractions were stored at 
–20 ºC until required.  Fractions were reconstituted in incubation 
buffer for subsequent experiments as required.
Background
The 21st century has seen increasing globalization, 
industrialization, longevity and major changes in lifestyle throughout 
the world.  Because of these changes, projections indicate that by 
2025, more than 5% of the world population will have diabetes [1,2]. 
In addition to this rapid increase in incidence, challenges facing the 
treatment and management of diabetes include known inefficacies 
of currently available therapies. This has created the need for novel 
treatment strategies that offer more benefits to people suffering from 
type 2 diabetes, focusing on treatments that produce better glycaemic 
control, appetite regulation, blood pressure and lipid reduction and 
weight loss [3]. 
Before the discovery of insulin in 1922, dietary treatments and 
plant-based therapies were commonly used for diabetes management. 
Over several decades, a number of comprehensive reviews have 
documented the utility of higher plants for treating aspects of 
diabetes, also providing discussion of the botany, photochemistry, 
pharmacology, and toxicology of botanical agents [4-8]. Previous 
studies in our laboratory have also provided research evidence for the 
anti-diabetic potential of extracts of various plant species [9-11]. 
Terminalia arjuna is a large tree belonging to the family 
Combretaceae, (Roxb Wight Arn) and indigenous to India, Myanmar 
and Sri Lanka. The bark of T. arjuna has been used in Indian 
native Ayurvedic medicine for over three centuries, primarily as a 
cardiotonic [12]. The bark of Terminalia arjuna has been found to 
have therapeutic benefit for the treatment of cardiovascular disease 
[13]. Clinical research has indicated its usefulness in relieving angina 
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Insulin secretion 
Insulin release was determined using monolayers of clonal 
pancreatic cells, BRIN-BD11 [16].  Cells were grown in RPMI-1640 
tissue culture medium containing 11.1 mmol glucose/l, 10 % foetal 
calf serum and antibiotics (50,000 IU penicillin-streptomycin/l), 
and maintained at 37 ºC in an atmosphere of 5 % CO2 and 95 % air. 
Twenty-four hours prior to acute experiments, cells were harvested 
and seeded in 24 - well plates at a density of 1.0 x 105 cells per well. 
Following overnight attachment, culture medium was removed and 
cells were pre-incubated for 40 min at 37 ºC with 1 mL of krebs 
ringer bicarbonate (KRB) buffer supplemented with 1.1 mM glucose 
and 1 % bovine serum albumin (BSA). Subsequent test incubations 
were performed for 20 min at 5.6 mM glucose using similar buffer 
supplemented with aqueous plant extract and the agents indicated 
in Figures.  Samples were stored at –20 ºC for subsequent insulin 
radioimmunoassay [17]. Cell viability was assessed by a modified 
neutral red assay as described previously [18].
Intracellular calcium ([Ca2+]i) 
Changes in [Ca2+]i were determined fluorimetrically [19] 
using monolayers of BRIN-BD11 cells. The fluorescent probes 
are internalised by living cells during pre-incubation and emit 
characteristic fluorescence in relation to changes in cellular [Ca2+]
 
i. Cells were seeded into 96-well plates (black walls, clear bottom, 
Costar, Roskilde, Denmark) at a density of 1.0 x 105 viable cells 
per well and allowed to attach overnight in culture.  The cells were 
washed once with KRB buffer (115 mM NaCl, 4.7 mM KCl, 1.28 mM 
CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 10 mM NaHCO3 and 0.1 
% (w/v) bovine serum albumin, pH 7.4) supplemented with 5.6 mM 
glucose, 20 mM HEPES and 500 µM of probenecid.  The cells were 
incubated at 37 ºC, for 1 hour with Ca2+ assay kit (Molecular Devices, 
Sunnyvale, California, USA), prepared with the same washing buffer, 
to a final volume of 200 µL.  Fluorimetric data were acquired using 
a Flex Station scanning fluorimeter with integrated fluid transfer 
workstation (Molecular Devices, Sunnyvale, California, USA). 
Excitation, emission and cut-off filter were set to 485 nm, 525 nm and 
515 nm.  The Flexstation was set to run for 10 minutes, collecting data 
at a 2.5 second interval (6 reads per well).  Test solutions (50 µL at 5X 
concentration) were transferred at 60 seconds from start of readings 
at a rate of 78 mL/s.   
Adipocyte differentiation and cellular glucose uptake
3T3-L1 fibroblasts obtained from the American Type Culture 
Collection ((ATCC) Virginia, USA), were used to determine glucose 
uptake [20]. Cells (passages 5-10) were seeded in 12-well plates at a 
density of 1.0 x 105 cells per well, maintained at 37ºC ± 2 ºC with 5 % 
CO2 and fed every 2 days with DMEM supplemented with penicillin 
(50 U/mL), streptomycin (50 µl/mL) and foetal bovine serum (10 % 
v/v).   Adipocyte differentiation was initiated as described in detail 
elsewhere by the addition of 1 µg/mL insulin, 0.5 mM IBMX and 0.25 
µM dexamethosone [20].  Prior to acute tests, cells were incubated in 
serum free DMEM for 2-3 hours to establish basal glucose uptake. 
Cellular glucose uptake was determined for 15 min at 37 ºC using 
KRB buffer supplemented with tritiated 2-deoxyglucose (0.5 µCi/
well), 50 mM glucose, insulin and other test agents as indicated in 
the Figures.  Hexose uptake was terminated after 5 minutes by three 
rapid washes with ice-cold PBS, after which cells were detached by the 
addition of 0.1 % sodium dodecyl sulphate (SDS) and subsequently 
lysed.  Scintillation fluid was added and mixed thoroughly to solubilise 
the cell suspension.  Radioactivity was measured on a Wallac 1409 
Scintillation Counter (Wallac, Turke, Finland). 
Starch digestion
To assess in vitro starch digestion, 100 mg of soluble starch 
(Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 3 ml of distilled 
water in the absence and presence of plant extract or acarbose 50 µg/
ml (Bayer AG, Germany) as a positive control. 40 µl of 0.01 % heat 
stable α-amylase (from Bacillus leicheniformis), Sigma-Aldrich, St. 
Louis, USA) was added to all tubes.  After incubation at 80ºC for 20 
minutes, the mixture was diluted to 10 ml and 1 ml was incubated 
with 2 ml of 0.1 M sodium acetate buffer (pH 4.75) and 30 µL of 0.1 
% amyloglucosidase from Rhizopus mold (Sigma-Aldrich, St. Louis, 
USA) for 30 minutes at 60 ºC. Glucose released, was measured on the 
Analox GM9 glucose analyzer (Analox Instruments, London, UK). 
Protein glycation
A simple in vitro system was employed to assess protein glycation 
based, using insulin as a model substrate [21]. In brief, 100 µl of human 
insulin (1 mg/ml) was incubated in 10 mM sodium phosphate buffer 
(pH 7.4) with 220 mM D-glucose, plant extract or aminoguanidine 
(positive control) for 24 h.  Sodium cyanoborohydride was added and 
the reaction was stopped by addition of 0.5 M acetic acid.  Glycated 
and non-glycated insulin were separated and quantified using 
reversed-phase high performance liquid chromatography [21].   
Statistical analysis
All results are expressed as mean ± SEM for a given number 
of observations (n).  Groups of data were compared statistically 
using one-way ANOVA test followed by Newman-Keul post hoc 
comparison for data sets with p < 0.05.
Results
Insulin secretion studies
Aqueous extract of Terminalia arjuna produced a dose-
dependent increase in insulin secretion from BRIN-BD11 cells at 
5.6 mM glucose (5 mg/ml and above, n=8, p<0.001, Figure 1A).  Cell 
viability assessed by neutral red assay remained was unchanged with 
the increase in insulin release (Figure 1B).  The extract significantly 
enhanced insulin secretion at lower (1.1 mM) and higher (16.7 
mM) glucose concentrations, P<0.001, n=8), (Figure 2). The insulin 
secretory activity of the extract was partially inhibited by verapamil 
(50µM, 39%, P<0.01) and diazoxide (300µM, 34%, P<0.01), (Figure 
2).  Furthermore, insulin secretion was further enhanced (2-fold, 
p<0.001) in the presence of the plant extract (5mg/ml) and IBMX 
(100µM). The plant extract produced no significant enhancement 
of insulin secretion in the presence of depolarizing concentration 
of KCl (Figure 2). Insulin release elicited by glibenclamide (200µM) 
and tolbutamide (200µM) also increased by 130% (p<0.001) and 
170% (p<0.001) respectively in the presence T. arjuna.  The insulin 
secretary activity Terminalia arjuna was abolished in the absence 
calcium (Figure 3).
Intracellular calcium [Ca2+]I studies
 Aqueous Terminalia arjuna extract (5 mg/ml) induced a sharp 
rise followed by a sustained increase in [Ca2+]i (Figure 4A).  Addition 
Austin J Endocrinol Diabetes 1(1): id1001 (2014)  - Page - 03
Yasser H. A. Abdel-Wahab Austin Publishing Group







Glucose (5.6mM) + Alanine (10mM)
Glucose (5.6mM) + Aqueous extract of T. arjuna






























Glucose (5.6mM) + Alanine (10mM)
Glucose (5.6mM) + Aqueous extract of T. arjuna
None None 0.01 0.05 0.10 0.50 1.00 5.00 10.00 25.00
(B)















Figure 1: Dose-dependent effects of Terminalia arjuna on insulin secretion 
from BRIN: BD11 cells. BRIN-BD11 cells were incubated in KRB buffer 
supplemented with 5.6mM glucose in the presence or absence of increasing 
concentrations of plant extract for 20 min. Concentration of insulin and cell 
viability were measured in the supernatant retrieved after incubation period. 
Values are mean ± SEM with n = 8 for insulin and n = 6 for cell viability. 
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Figure 2: Modulation of Terminalia arjuna extract-induced insulin secretion 
by established stimulators and inhibitors of beta cell function.  Values are 
mean ± SEM of 8 separate observations.  **P<0.01, ***P<0.001 compared 
to glucose (control) in presence or absence of plant extract.  ∆∆P<0.01, 
∆∆∆P<0.001 compared to the respective incubations in absence of plant 
extract. ++P<0.01, +++P<0.001 compared to 16.7mM glucose in presence or 
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Figure 3: Effects of extracellular calcium on insulin release by Terminalia 
arjuna. BRIN-BD11 cells were incubated in calcium-containing or calcium-
free KRB buffer supplemented with 5.6mM glucose in the presence or 
absence of plant extract for 20 min. Values are mean ± SEM of 8 separate 
observations.  ***P<0.001 compared to 5.6mM glucose in the presence of 
Ca2+.  ∆∆∆P<0.001 compared to the respective concentration in the presence 
of Ca2+.  +++P<0.001 compared to 5.6mM glucose in the absence of Ca2+.

























































Figure 4: Effects of Terminalia arjuna on intracellular Ca2+ influx in the absence 
(A) and presence of Verapamil (B).  Intracellular calcium concentration were 
measured by fluorescence spectroscopy in BRIN-BD11 cells incubated with 
KRB buffer containing FLIPR calcium dye and 5.6mM glucose in the presence 
or absence of plant material (5mg/ml) (Figure 4A). Verapamil (50µM) was 
added 60 seconds after the commencement of the experiment in Figure 4B. 
Data was collected every 1.25 seconds over a period of 540 seconds. Values 
are mean ± SEM of 6 separate observations.
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of verapamil (50µM) resulted in a marked and sustained reduction in 
the sharp rise of [Ca2+]i (Figure 4B). 
Glucose uptake in vitro
Exposure of 3T3-L1 cells to aqueous extract of Terminalia arjuna 
produced a 178% increase in glucose uptake compared to control 
(p<0.01, Figure 5).  This effect was greater than the effects of insulin 
alone (10-9M, p<0.01, Figure 5).  Concurrent incubation of the extract 
(5mg/ml) and insulin (10-9M) resulted in 96% (p<0.01) increase in 
glucose uptake compared to insulin alone (Figure 5).     
Starch digestion
In the presence of acarbose (1 mg/ml, positive control), enzymatic 
glucose liberation from starch was inhibited by 90% (P<0.001) 
compared to control.  Aqueous extract of T. arjuna also significantly 
inhibited starch digestion at concentrations >10mg/ml. The highest 
inhibitory effect (74%, P<0.001) was observed at 50 mg/ml of the 
plant extract (Figure 6). 
Protein glycation 
Aqueous extract of Terminalia arjuna exerted a partial inhibition 
of insulin glycation (Figure 7). Over a range of concentrations tested 
(1-10 mg/ml), the plant extract significantly decreased protein 
glycation by 42% to 69% (p<0.001, Figure 7).  
Discussion
Aqueous extract of Terminalia arjuna, stimulated insulin from 
BRIN-BD11 cells dose-dependently at concentrations ≥ 5 mg/ml. 
The stimulatory effects were not associated with beta cell cytotoxicity, 
confirming that the observed insulinotropic action was not due to 
simple leakage of insulin from the cells.  Chelation of extracellular 
Ca2+ also inhibited the stimulatory effect of the plant extract, 
suggesting that Ca2+ plays an important role in the mode of action 
of the plant constituents.  T. arjuna maintained its insulin-releasing 
effects; albeit at lower level, in the presence of verapamil (an inhibitor 
of voltage-gated Ca2+ channels) or diazoxide (K-ATP channels opener) 
[22]. This indicates that the insulinotropic effects may also involve 
an additional Ca2+-independent pathway.  The extract also enhanced 
the insulinotropic activity of sulphonylureas tested, consistent with 
a potentiation of the KATP-channel dependent activities of these 
secretagogues. This was confirmed by substantial rise of intracellular 
calcium ([Ca2+]i) in response to T. arjuna which was attenuated but 
not completely abolished by verapamil.  This rise in [Ca2+]i is probably 
a result of the opening of the voltage dependent calcium channels 
(VDCC) due to beta cell-depolarizing effects. The physiologic nature 
of this observation was confirmed by the attenuation of the increase 
in [Ca2+]i by Ca
2+ channel blockade with verapamil. The importance of 
plasma membrane action was also evidenced by no further stimulation 




























Figure 5: Effects of Terminalia arjuna extracts on 2-deoxy-D-[H3] glucose 
transport. Results are mean ± SEM of 4 separate observations. ***P<0.001 
compared with incubations in the absence of insulin. +++P<0.001 compared 
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Figure 6: Effects of Terminalia arjuna extracts on starch digestion Soluble 
starch (100 mg) was dissolved in water in the absence or presence plant 
material or acarbose (50 µg/ml, positive control) and incubated at 80ºC for 
20 minutes prior to measurement of the concentration glucose liberated. 
Results are mean ± SEM of 3 separate observations.  ***P<0.001 compared 
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Figure 7:  Effects of Terminalia arjuna extract on protein glycation. Results 
are mean ± SEM of 3 separate observations. **P<0.01, ***P<0.001 compared 
to glycation in the absence of plant extract.
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In addition to the prominent beta cell stimulatory effects, aqueous 
extract of Terminalia arjuna enhanced cellular glucose transport in 
differentiated 3T3-L1 adipocytes.  This effect was evident at lower 
concentration. The stimulatory action of insulin (10-9  M) was also 
augmented in the presence of the extract and the combined actions 
of the extract plus insulin exceeded the effects of either agent alone. 
As previously documented [15], the presence of trace elements in 
Terminalia arjuna bark extract may be one factor contributing to its 
ability to enhance insulin action [23,24]. 
Using a simple in vitro test consisting of the digestive enzymes 
α-amylase and α−glucosidase, the potential of Terminalia arjuna to 
retard starch digestion was evaluated by its effect on glucose liberation 
from starch.   In this system, the established α-glucosidase inhibitor, 
acarbose, completely inhibited glucose liberation. In contrast, 
Terminalia arjuna extract produced a significant reduction in starch 
digestion at relatively higher concentrations of 10 mg/ml and above. 
Components of the extract responsible for this effect are unknown 
but the bark of Terminalia arjuna has been shown to contain high 
amounts of fiber [25] which may impede nutrient absorption in vivo. 
Ram et al. [14] demonstrated that bark extract of T. arjuna decreased 
deposition of fat in the liver and heart of rabbits.   
In the final series of experiments, the ability of Terminalia 
arjuna aqueous extract to inhibit protein glycation was assessed 
using insulin as a model substrate [21]. The choice of insulin was 
based on the biological significance of glycated insulin with respect 
to pathophysiology of diabetes. It has been reported that glycated 
insulin exists in vivo and has reduced biological activity [26,27]. 
In this simple system, aqueous extract of Terminalia arjuna, 
significantly decreased glycation of insulin at concentrations ≥1mg/
ml. Ethanolic extract of Terminalia arjuna has been reported to 
contain constituents such as tannins, flavonoids and glycosides 
which exhibit significant antioxidant properties [28]. Thus, the anti-
glycation effects demonstrated in the present investigation may be a 
result of the antioxidative properties of some of its constituents.
Conclusion
In conclusion, aqueous bark extracts stimulated insulin secretion, 
enhanced insulin action, inhibited starch digestion and prevented 
protein glycation. The ability of plant constituents to influence these 
parameters in vivo depends entirely on soluble active principle(s) 
being absorbed via the gut.  Further work is required to assess the 
ability of Terminalia arjuna to exert antidiabetic effects in vivo. 
Identification of the active components of the plant and assessment 
of in vivo activities are also critical to the possible development into 
new agents for diabetes therapy.
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